Delcath Systems Inc

NASDAQ:DCTHUnited States

Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.

Contact Information

Headquarters

1633 Broadway Ste 22CNEW YORK, NY, United States 10019-6708

Phone

212-489-2100

Fax

212-489-2102

Executives

Independent Chairman of the Board

John Sylvester

Chief Executive Officer, Director

Gerard Michel

Chief Operating Officer, Executive Vice President - Global Head of Operations

John Purpura

Senior Vice President - Clinical Development and Medical Affairs

Johnny John

Chief Compliance Officer, General Counsel, Corporate Secretary

David Hoffman